Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitazoxanide in Colds Due to Enterovirus/Rhinovirus
NCT03605862Phase 3Completed
- Sponsor
- Romark Laboratories
- Start
- Sep 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in enterovirus infection and rhinovirus infection comparing Nitazoxanide with Placebo (2 arms). Primary endpoint: Time From First Dose to Symptom Response Based Upon the FLU-PRO Instrument up to 21 days. Started Sep 2018; status: completed.
02
Drugs
nitazoxanide
03
Conditions
enterovirus infectionrhinovirus infection
Beyond the preview
Go deeper on NCT03605862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03605862.